Banka BioLoo Ltd. (BANKA) AI Stock Analysis

• Market Cap: ₹528.55M
• Dividend Yield: N/A
• Average Volume (3M): 13.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: -4.57%
• EPS Growth: 23.01%
• Country: IN
• Employees: 1,111
• Sector: Services
• Sector Strength: N/A
• Industry: Industrial - Pollution & Treatment Controls
• EPS (TTM): -0.14
• Shares Outstanding: 10,846,582
• 10 Day Avg. Volume: 8,574
• 30 Day Avg. Volume: 13,495
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.48
• Price to Sales (P/S): 1.44
• P/FCF Ratio: -11.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ₹47.00 ▼(-29.62% Downside)
• Action: Upgraded Date: 12/03/25
• Date: Action: Upgraded 12/03/25

Banka BioLoo Ltd. faces significant financial and technical challenges, with declining revenues, negative profitability, and bearish market momentum. The negative P/E ratio and lack of dividend yield further weaken its valuation. These factors collectively result in a low overall stock score.

Positive Factors

Moderate leverage

A moderate debt-to-equity ratio suggests the company has used leverage without overextending, preserving financial flexibility. Over 2-6 months this supports funding of projects and working capital needs while avoiding excessive interest burden that would worsen during operating weakness.

Recurring service revenue stream

Having service and maintenance contracts alongside product and project sales creates a durable revenue mix. Service revenue tends to be more predictable and higher margin over time, supporting cash generation and customer retention even if new unit sales fluctuate.

Structural market demand

The company's focus on sanitation for areas without sewerage addresses a persistent infrastructure gap. Structural public and institutional demand for on-site waste treatment is long-term, supporting a steady addressable market for installations, upgrades, and recurring O&M work.

Negative Factors

Declining revenue & profitability

Sustained declines in revenue and persistent negative EBIT and net income indicate structural operational issues. Over months this erodes margins, reduces reinvestment capacity, and undermines the company's ability to scale or compete without significant improvement in sales or cost structure.

Negative operating and free cash flow

Negative operating and free cash flow imply the business cannot internally fund capital expenditures or working capital needs. This creates reliance on external financing, increases liquidity risk, and limits the firm's ability to sustain maintenance programs or execute growth projects over the medium term.

Shrinking shareholders' equity

Declining shareholders' equity signals accumulated losses or balance-sheet erosion, reducing the company's capital cushion. Over time this weakens creditworthiness, constrains borrowing capacity, and raises the risk that adverse shocks could force dilutive equity raises or distress restructuring.

Banka BioLoo Ltd. Business Overview & Revenue Model

Company Description

Banka BioLoo Limited provides products and services for sanitation and waste management system in India. It manufactures, supplies, and installs bio-toilets. The company is also involved in the operation and maintenance of bio-toilets for Indian railways; setting-up of fecal sludge treatment plants and packaged sewage treatment plants; and refurbishment of sewage treatment plants for complexes. The company was incorporated in 2012 and is based in Hyderabad, India.

How the Company Makes Money

Banka BioLoo Ltd. generates revenue primarily by selling bio-toilet (bio-digester) systems and related sanitation products to customers that need on-site human-waste treatment where sewer connections are unavailable or impractical. Key revenue streams include: (1) product sales of bio-toilet units, bio-digester tanks, and associated hardware/consumables; (2) project and execution income tied to the supply, installation, and commissioning of these systems for institutional or large-scale deployments; and (3) service revenue from after-sales activities such as operation/maintenance contracts, periodic servicing, and replacements/spares where applicable. Any material contribution from specific named partnerships, customer concentration, pricing terms, or segment-level revenue splits is null.

Banka BioLoo Ltd. Financial Statement Overview

Summary

Banka BioLoo Ltd. is facing significant financial challenges, with declining revenues, negative profitability, and cash flow difficulties. The moderate debt-to-equity ratio is a positive aspect, but overall financial health is under pressure due to shrinking equity and persistent losses.

Income Statement

Banka BioLoo Ltd. has experienced a decline in revenue and profitability over the years. The gross profit margin has decreased significantly from a strong position, and the company is currently reporting negative EBIT and net income, indicating challenges in profitability and operational efficiency. The revenue growth rate has been negative in the most recent year, highlighting a contraction in sales.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the stockholders' equity has been decreasing, reflecting potential financial strain. The equity ratio remains stable but does not offset the risks associated with declining equity and increasing liabilities.

Cash Flow

Cash flow analysis reveals a negative free cash flow, indicating the company's inability to generate sufficient cash to cover its capital expenditures. The operating cash flow has also turned negative recently, which is concerning for sustaining operations without external financing. The free cash flow to net income ratio is unfavorable, pointing towards cash flow difficulties.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	530.30M	541.74M	499.96M	423.50M	387.51M	304.58M
Gross Profit	262.07M	9.87M	337.57M	368.11M	320.30M	266.47M
EBITDA	14.70M	-28.60M	41.85M	66.06M	58.91M	39.31M
Net Income	-41.50M	-89.09M	-6.53M	25.39M	31.08M	22.05M
Balance Sheet
Total Assets	801.17M	821.55M	774.23M	652.07M	640.54M	463.71M
Cash, Cash Equivalents and Short-Term Investments	19.66M	40.70M	16.88M	13.41M	8.29M	43.35M
Total Debt	323.93M	347.28M	259.13M	167.15M	184.96M	116.99M
Total Liabilities	494.26M	505.70M	376.61M	251.09M	265.52M	163.43M
Stockholders Equity	306.25M	315.13M	397.20M	400.99M	375.02M	300.28M
Cash Flow
Free Cash Flow	11.47M	-69.53M	-72.06M	9.40M	-36.00M	53.55M
Operating Cash Flow	42.83M	-24.71M	27.63M	73.53M	-4.40M	58.64M
Investing Cash Flow	-5.01M	-63.44M	-100.69M	-57.18M	-27.17M	-283.29K
Financing Cash Flow	-39.54M	87.50M	67.76M	-33.29M	9.55M	-36.86M

Banka BioLoo Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 66.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BANKA, the sentiment is Negative. The current price of 66.78 is above the 20-day moving average (MA) of 53.57, above the 50-day MA of 58.59, and below the 200-day MA of 74.12, indicating a bearish trend. The MACD of -3.34 indicates Positive momentum. The RSI at 26.70 is Positive, neither overbought nor oversold. The STOCH value of 29.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BANKA.

Banka BioLoo Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPECIALITY	56 Neutral	₹4.65B	15.98	―	0.87%	6.66%	-21.40%
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
MAHEPC	54 Neutral	₹3.21B	13.84	―	―	17.09%	―
BANKA	41 Neutral	₹528.55M	-122.34	―	―	-4.57%	23.01%
IL&FSENGG	40 Underperform	₹3.28B	-229.15	―	―	-6.13%	98.35%